Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC) Meeting Abstract
| Authors: | Motzer, R. J.; Porta, C.; Alekseev, B.; Rha, S. Y.; Choueiri, T. K.; Mendez-Vidal, M. J.; Hong, S. H.; Kapoor, A.; Goh, J. C.; Eto, M.; Wang, J.; Pan, J.; Asfaw, A. A.; He, C. S.; Mody, K.; Cella, D. |
| Abstract Title: | Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120602251 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.4502 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4502 -- Source: Wos |
